| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2014 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
| SC 13G/A | 2023-03-21 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.